This article is more than 5 years old. Information may no longer be current.
ColonaryConcepts targets phase 3 trial for edible colonoscopy prep
A novel colonoscopy preparation designed to be more palatable for patients could be headed to a phase 3 trial next year after ColonaryConcepts announced it has reacquired its rights.
Originally sold to Sebela Pharmaceuticals in 2017, EC Prep integrates active colonoscopy prep ingredients into “nutritionally balanced bars” and beverages, according to a press release.
“EC Prep is a paradigm-shift in colon prep,” Herbert Stern, CEO of ColonaryConcepts, said in the release. “We remain convinced that millions of patients will benefit from the advance in colonoscopy prep that ColonaryConcepts’ team has developed and are delighted to propel this technology forward.”
In a phase 2a trial presented in 2016, more than 90% of patients using the lead formulation of EC Prep had excellent or good rated colonoscopies. Additionally, patients reported high satisfaction with the prep, especially compared with preps they previously used.
“We are pleased to reengage in the clinical development of EC Prep,” Stern said in the release. “We are excited to accelerate into phase 3 clinical trials, targeting mid-2020.”
Through its subsidiary, ColonarySolutions, the company is also developing chewable bars, known as C-Bar, as a treatment for patients with chronic idiopathic constipation. Planning for a phase 2 clinical trial is currently in the works.
Reference: